Showing results (91-100 of 142) with videos related to
Sort By:
Pageof 15
The Lancet. Haematology|October 7, 2018
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 studyFranco Locatelli, Christine Mauz-Koerholz, Kathleen Neville, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumorsMichele Basche, Daniel L Gustafson, Scott N Holden, et al.Cancer|December 22, 2017
Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131Wanda L Salzer, Michael J Burke, Meenakshi Devidas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium studyRochelle Bagatell, Lia Gore, Merrill J Egorin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2024
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group StudySarah Alexander, John A Kairalla, Sumit Gupta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621Maureen M O'Brien, Lingyun Ji, Nirali N Shah, et al.Pediatric Blood & Cancer|April 1, 2018
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemiaAndrew E Place, Yana Pikman, Kristen E Stevenson, et al.Pediatric Blood & Cancer|November 20, 2014
Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology GroupWanda L Salzer, Tamekia L Jones, Meenakshi Devidas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersAlex A Adjei, Roger B Cohen, Wilbur Franklin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2Jennifer L Spratlin, Roger B Cohen, Matthew Eadens, et al.Pageof 15